Results 1 to 10 of about 38,006 (217)

Tolerability of SGLT2 inhibitors in patients with Fabry disease: An observational study [PDF]

American Heart Journal Plus
Cardiac involvement of Fabry disease (FD) includes heart failure (HF) treated according to general guideline recommendations. The retrospective study investigates HF medication in FD focusing on sodium glucose cotransporter 2 (SGLT2) inhibitors.
Isabel Mattig, Berit Zirkelbach, Carina Bonnekoh, Karl Stangl, Gerhard Hindricks, Fabian Knebel, Sima Canaan-Kühl, Sebastian Spethmann   +7 more
doaj   +2 more sources

Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Water and Sodium Metabolism

Frontiers in Pharmacology, 2022
Sodium-glucose cotransporter 2 (SGLT2) inhibitors exert hypoglycemic and diuretic effects by inhibiting the absorption of sodium and glucose from the proximal tubule.
Jun Tang, Jun Tang, Lifang Ye, Lifang Ye, Qiqi Yan, Qiqi Yan, Xin Zhang, Xin Zhang, Lihong Wang, Lihong Wang   +9 more
doaj   +1 more source

Safety of four SGLT2 inhibitors in three chronic diseases: A meta-analysis of large randomized trials of SGLT2 inhibitors

Diabetes & Vascular Disease Research, 2021
There are no relevant meta-analyses that have assessed the safety of the sodium-glucose transporter 2 (SGLT2) inhibitors in different chronic diseases. We aimed at evaluating the safety of four SGLT2 inhibitors in three chronic diseases by meta-analysis ...
Mei Qiu, Liang-Liang Ding, Miao Zhang, Hai-Rong Zhou   +3 more
doaj   +1 more source

Electrocardiographic changes associated with SGLT2 inhibitors and non-SGLT2 inhibitors: A multi-center retrospective study

Frontiers in Cardiovascular Medicine, 2022
BackgroundSodium-glucose co-transporter 2 (SGLT2) inhibitors has been shown with cardiovascular benefit in type 2 diabetes mellitus (T2DM) patients. However, its osmotic diuresis still concern physicians who may look for possible electrolyte imbalance ...
Victor Chien-Chia Wu, Kai-Pin Chiu, Chun-Li Wang, Chiu-Yi Hsu, Hui-Tzu Tu, Yu-Tung Huang, Chih-Hsiang Chang, Chien-Hao Huang, Chang-Fu Kuo, Chang-Fu Kuo, Shao-Wei Chen, Shao-Wei Chen, Pao-Hsien Chu, Shang-Hung Chang, Shang-Hung Chang, Shang-Hung Chang   +15 more
doaj   +1 more source

Pleiotropic effect of sodium-glucose cotransporter 2 inhibitors on blood pressure

Frontiers in Cardiovascular Medicine, 2022
Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been incorporated as guideline-directed medical therapy for heart failure with reduced ejection fraction.
Ting-Wei Kao, Ting-Wei Kao, Chin-Chou Huang, Chin-Chou Huang, Chin-Chou Huang, Chin-Chou Huang   +5 more
doaj   +1 more source

Risk of diabetic ketoacidosis of SGLT2 inhibitors in patients with type 2 diabetes: a systematic review and network meta-analysis of randomized controlled trials

Frontiers in Pharmacology, 2023
Background: Sodium–glucose cotransporter-2 (SGLT2) inhibitors have proven to be effective in improving glycemic control in patients with type 2 diabetes mellitus (T2DM). However, the risk of diabetic ketoacidosis (DKA) in patients remains unclear.
Shiwen Yang, Ying Liu, Shengzhao Zhang, Fengbo Wu, Dan Liu, Qingfang Wu, Hanrui Zheng, Ping Fan, Na Su, Na Su   +9 more
doaj   +1 more source

The association between SGLT2 inhibitors and new-onset arrhythmias: a nationwide population-based longitudinal cohort study

Cardiovascular Diabetology, 2020
Background Clinical trials have shown the cardiovascular protective effect of sodium–glucose cotransporter-2 (SGLT2) inhibitors and reduced hospitalization for heart failure. However, no study has investigated the association between SGLT2 inhibitors and
Hung-Yi Chen, Jing-Yang Huang, Wun-Zhih Siao, Gwo-Ping Jong   +3 more
doaj   +1 more source

Benefits of SGLT2 inhibitors in arrhythmias

Frontiers in Cardiovascular Medicine, 2022
Some studies have shown that sodium-glucose cotransporter (SGLT) 2 inhibitors can definitively attenuate the occurrence of cardiovascular diseases such as heart failure (HF), dilated cardiomyopathy (DCM), and myocardial infarction.
Jinghan Gao, Genlong Xue, Ge Zhan, Xinying Wang, Jiatian Li, Xiaolei Yang, Yunlong Xia   +6 more
doaj   +1 more source

Favorable pleiotropic effects of sodium glucose cotransporter 2 inhibitors: head-to-head comparisons with dipeptidyl peptidase-4 inhibitors in type 2 diabetes patients

Cardiovascular Diabetology, 2020
Background Sodium glucose cotransporter 2 (SGLT2) inhibitors have shown greater reductions of cardiovascular event risks than dipeptidyl peptidase-4 (DPP4) inhibitors, whereby possible mechanisms may involve the better pleiotropic effects of SGLT2 ...
Shih-Chieh Shao, Kai-Cheng Chang, Swu-Jane Lin, Rong-Nan Chien, Ming-Jui Hung, Yuk-Ying Chan, Yea-Huei Kao Yang, Edward Chia-Cheng Lai   +7 more
doaj   +1 more source

SGLT2 Inhibitors Play a Salutary Role in Heart Failure via Modulation of the Mitochondrial Function

Frontiers in Cardiovascular Medicine, 2020
Three cardiovascular outcome trials of sodium glucose cotransporter 2 (SGLT2) inhibitors, including the EMPA-REG OUTCOME trial, CANVAS Program, and DECLARE TIMI 58 trial, revealed that SGLT2 inhibitors were superior to a matching placebo in reducing ...
Yasuhiro Maejima
doaj   +1 more source